Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CALCIUM CHLORIDE 10% vs ENOXAPARIN SODIUM
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Calcium chloride dissociates to provide calcium ions, which are essential for myocardial contractility, nerve impulse transmission, and blood coagulation. It antagonizes the cardiotoxic effects of hyperkalemia by stabilizing cardiac cell membrane potential.
Enoxaparin binds to antithrombin III (ATIII) via its pentasaccharide sequence, enhancing ATIII-mediated inhibition of factor Xa and, to a lesser extent, factor IIa (thrombin). It preferentially inhibits factor Xa over thrombin (anti-Xa:anti-IIa ratio ~3.6:1).
Emergency treatment of hypocalcemic tetany,Cardiac resuscitation in the presence of hyperkalemia or hypocalcemia,Treatment of calcium channel blocker overdose,Treatment of magnesium sulfate overdose,Management of acute hypermagnesemia,Used in cardiac surgery to reverse citrate anticoagulation
Prophylaxis of deep vein thrombosis (DVT) in abdominal or hip/knee replacement surgery,Prophylaxis of DVT in medical patients with acute illness and restricted mobility,Inpatient treatment of acute DVT with or without pulmonary embolism (PE) when administered with warfarin,Outpatient treatment of acute DVT without PE when administered with warfarin,Unstable angina and non-ST-segment elevation myocardial infarction (NSTEMI) when administered with aspirin,Acute ST-segment elevation myocardial infarction (STEMI) managed medically or with percutaneous coronary intervention (PCI)
IV: 500 mg to 1 g (5-10 m L of 10% solution) administered slowly at a rate not exceeding 0.5-1 m L/min; may be repeated every 1-3 days based on serum calcium levels.
1 mg/kg subcutaneous every 12 hours or 1.5 mg/kg subcutaneous once daily
Terminal half-life ~4-6 hours for rapid distribution phase; prolonged in renal impairment (up to 24-48 hours).
4.5-7 hours after single subcutaneous dose; prolonged to 8-12 hours in renal impairment (Cr Cl <30 m L/min). Clinical context: maintains anti-Xa activity for 12 hours with once-daily dosing.
Calcium chloride is not metabolized; it is excreted primarily in the urine with reabsorption regulated by the kidneys and parathyroid hormone.
Enoxaparin is partially metabolized in the liver via desulfation and depolymerization by heparanase and other enzymes. It has a complex pharmacokinetic profile with dose-dependent clearance; renal excretion accounts for elimination of active fragments and the unchanged drug.
Primarily renal (>80% as ionized calcium); minor fecal elimination (10-20%) via endogenous secretion; negligible biliary excretion.
Renal (40-60% as unchanged drug via glomerular filtration and saturable tubular reabsorption). Biliary/fecal: negligible (<10%).
Approximately 45-50% bound to albumin; 10-15% complexed with citrate, phosphate, or bicarbonate.
80% bound to antithrombin III (low affinity to other plasma proteins).
0.3-0.4 L/kg (primarily extracellular fluid). Increased in hypocalcemia or hypoalbuminemia.
0.04-0.06 L/kg (plasma volume distribution; low Vd indicates limited extravascular distribution).
IV/IO: 100%. Not administered orally for systemic effect due to GI irritation and poor absorption; oral bioavailability is negligible (<1%) if ingested.
Subcutaneous: 90-92% (complete absorption).
e GFR <30 m L/min: Use with caution, reduce dose by 50% and monitor serum calcium closely; e GFR <15 m L/min: Avoid use if possible, if necessary use lowest effective dose with frequent monitoring.
Cr Cl < 30 m L/min: reduce dose to 1 mg/kg subcutaneous once daily
No specific dose adjustment required for Child-Pugh class A, B, or C; monitor serum calcium due to potential for altered vitamin D metabolism.
No specific Child-Pugh based adjustment; use with caution in severe hepatic impairment due to increased bleeding risk
IV: 10-20 mg/kg of elemental calcium (0.1-0.2 m L/kg of 10% solution) given slowly (not exceeding 0.5 m L/min). Maximum single dose: 500 mg (5 m L). May repeat in 4-6 hours if needed.
Neonates and infants: 1.5 mg/kg subcutaneous every 12 hours; Children < 2 months: 1.5 mg/kg every 12 hours; Children ≥ 2 months: 1 mg/kg every 12 hours
Start at lower end of dosing range (e.g., 500 mg IV), administer at a slower rate (over 10-15 minutes) due to higher risk of hypercalcemia and cardiovascular effects; monitor renal function and serum calcium frequently.
Increased risk of bleeding; consider lower doses (e.g., 0.5 mg/kg every 12 hours or 1 mg/kg once daily) and monitor renal function
Rapid intravenous injection may cause cardiac arrest. Avoid extravasation as it causes severe tissue necrosis. Use with extreme caution in patients receiving digitalis glycosides due to risk of arrhythmias.
Enoxaparin carries a black box warning for the risk of spinal or epidural hematomas in patients receiving neuraxial anesthesia or spinal puncture, which can result in long-term or permanent paralysis. Patients should be monitored for signs of neurological impairment, and concomitant use of drugs affecting hemostasis (e.g., NSAIDs, antiplatelet agents, other anticoagulants) increases the risk.
Administer intravenously only; intramuscular or subcutaneous injection causes severe irritation and necrosis.,Use with caution in patients with renal impairment, sarcoidosis, or hypercalcemia.,Monitor serum calcium levels and electrocardiogram during administration.,Risk of bradycardia and arrhythmias, especially with concurrent digitalis therapy.,Rapid injection may cause vasodilation, hypotension, and cardiac arrest.
Spinal/epidural hematoma risk with neuraxial anesthesia,Increased bleeding risk, especially in patients with renal impairment, thrombocytopenia, or age >65,Heparin-induced thrombocytopenia (HIT) risk; monitor platelet counts regularly,Use with caution in patients with severe renal impairment (Cr Cl <30 m L/min), as enoxaparin accumulates and increases bleeding risk; dose adjustment required,Not recommended in patients with mechanical heart valves, especially pregnant women, due to risk of valve thrombosis,Do not mix with other injections or infusions
Hypercalcemia,Ventricular fibrillation during cardiac arrest (unless due to hypocalcemia),Severe hypercalciuria or calcinosis,Concurrent digitalis therapy (relative, may increase risk of arrhythmias)
Active major bleeding or bleeding disorders (e.g., hemophilia, thrombocytopenic purpura),History of heparin-induced thrombocytopenia (HIT) or heparin-induced thrombocytopenia and thrombosis (HITT),Hypersensitivity to enoxaparin, heparin, or pork products,Not recommended for use in patients with mechanical heart valves (especially pregnant women) due to risk of valve thrombosis,Concomitant use of other drugs that significantly increase bleeding risk (e.g., warfarin, aspirin, clopidogrel) without careful monitoring and indication
Avoid excessive intake of oxalate-rich foods (spinach, rhubarb, beets) and phytate-rich foods (bran, whole grains) as they may bind calcium and reduce absorption. Also limit sodium-containing foods to prevent calcium loss via urine. No direct food interactions with intravenous administration.
No specific food interactions. However, foods high in vitamin K (e.g., leafy greens) may theoretically affect coagulation but are not clinically significant with enoxaparin. Avoid excessive alcohol intake due to potential bleeding risk. Maintain consistent diet if also taking warfarin.
Animal reproduction studies have not been conducted with calcium chloride. It is not known whether calcium chloride can cause fetal harm when administered to a pregnant woman. Calcium is an essential mineral for fetal development; however, high doses may lead to hypercalcemia in the mother and fetus. In the first trimester, no specific teratogenic risk is documented; however, maternal hypercalcemia from excessive supplementation may interfere with placental calcium transport and fetal bone development. In the second and third trimesters, excessive doses may cause fetal hypoparathyroidism, hypercalcemia, and potential neonatal hypocalcemia due to suppression of the fetal parathyroid gland. Use only if clearly needed and with caution.
Enoxaparin sodium does not cross the placenta and is not associated with teratogenicity in humans. However, there is a risk of hemorrhage during delivery. Use during pregnancy requires careful monitoring for bleeding.
Calcium is excreted into breast milk. The M/P ratio for calcium is approximately 1.0 (range 0.9-1.1) reflecting passive diffusion and active transport. Intravenous calcium chloride administration may transiently increase maternal serum calcium levels, leading to a small increase in milk calcium concentration. However, this is unlikely to cause adverse effects in the breastfed infant. The American Academy of Pediatrics considers calcium supplementation compatible with breastfeeding. Use with caution and monitor infant for signs of hypercalcemia (e.g., constipation, irritability) if high doses are administered.
Excretion into breast milk is minimal; M/P ratio not determined. Considered compatible with breastfeeding; no known adverse effects in nursing infants, but monitor for bleeding signs.
Pregnancy is associated with increased plasma volume and enhanced renal clearance, potentially lowering serum calcium levels. However, calcium chloride is typically administered intravenously for acute hypocalcemia or cardiac resuscitation; no specific dose adjustments are recommended solely due to pregnancy. Use standard dosing based on the indication and severity of hypocalcemia, with close monitoring of serum calcium to avoid overdosage. The same caution applies: administer slowly (0.5-1 m L/min of 10% solution) and check ECG if rapid infusion.
Pregnancy increases volume of distribution and clearance of enoxaparin, necessitating dose adjustment. Monitor anti-Xa levels and adjust dose to maintain target levels, typically requiring higher doses per weight in late pregnancy.
Calcium chloride 10% (100 mg/m L) provides 13.6 m Eq/10 m L of calcium. It is highly irritating; administer via central venous line to avoid severe tissue necrosis if extravasation occurs. Do not mix with bicarbonate or phosphate solutions. In cardiac arrest, consider dose of 500-1000 mg IV push (repeat q10min if needed). Contraindicated in digitalis toxicity due to risk of fatal arrhythmias.
Enoxaparin is a low molecular weight heparin (LMWH) that preferentially inhibits factor Xa over thrombin. Monitor anti-Xa levels in patients with renal impairment (Cr Cl <30 m L/min), obesity, or pregnancy. Avoid intramuscular injections and use with caution in patients receiving neuraxial anesthesia due to risk of spinal hematoma. Protamine sulfate partially reverses enoxaparin (up to 60% of anti-Xa activity). Does not routinely require monitoring of a PTT.
This medication is given intravenously to treat calcium deficiency or certain emergencies.,You may experience a warm sensation, metallic taste, or flushing during injection.,Report any burning, pain, or redness at the injection site immediately.,Avoid taking digoxin (digitalis) unless specifically instructed by your doctor.,Do not stop or change the dose without consulting your healthcare provider.
Inject subcutaneously as directed, rotating injection sites (e.g., left/right abdomen, alternating).,Do not massage the injection site after administration.,Report any signs of bleeding: unusual bruising, prolonged bleeding from cuts, blood in urine or stool, coughing up blood.,Seek immediate medical attention for symptoms of spinal hematoma after neuraxial procedure: back pain, numbness or weakness in legs, bowel/bladder dysfunction.,Inform all healthcare providers (including dentists) that you are taking enoxaparin.,Avoid NSAIDs, aspirin, or other blood thinners unless prescribed by your doctor.
"Calcium chloride, an intravenous calcium salt, directly increases serum ionized calcium levels, which can antagonize the pharmacodynamic effects of the calcium channel blocker manidipine. Manidipine inhibits L-type calcium channels in vascular smooth muscle, leading to vasodilation and reduced blood pressure. Elevated extracellular calcium from calcium chloride administration can overcome this blockade, potentially diminishing the antihypertensive efficacy of manidipine and increasing the risk of hypertensive urgency or elevated blood pressure."
"Calcium chloride, a source of calcium ions, can chelate with bisphosphonates such as risedronic acid in the gastrointestinal tract, forming insoluble complexes that reduce the oral absorption of risedronic acid. This interaction may lead to decreased serum concentrations of risedronic acid, potentially compromising its therapeutic efficacy in preventing bone resorption. Patients may experience reduced bone mineral density or increased risk of fractures if the interaction is significant."
"Calcium chloride, a source of calcium ions, can chelate alendronic acid (a bisphosphonate) in the gastrointestinal tract, forming insoluble complexes that reduce the absorption of alendronic acid. This interaction can significantly decrease the systemic bioavailability and serum concentration of alendronic acid, potentially compromising its therapeutic efficacy in preventing bone resorption and treating osteoporosis. Clinically, patients may experience reduced bone mineral density improvement or increased fracture risk if the drugs are co-administered."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CALCIUM CHLORIDE 10% vs ENOXAPARIN SODIUM, answered by our medical review team.
CALCIUM CHLORIDE 10% is a Electrolyte Supplement that works by Calcium chloride dissociates to provide calcium ions, which are essential for myocardial contractility, nerve impulse transmission, and blood coagulation. It antagonizes the cardiotoxic effects of hyperkalemia by stabilizing cardiac cell membrane potential.. ENOXAPARIN SODIUM is a Low Molecular Weight Heparin that works by Enoxaparin binds to antithrombin III (ATIII) via its pentasaccharide sequence, enhancing ATIII-mediated inhibition of factor Xa and, to a lesser extent, factor IIa (thrombin). It preferentially inhibits factor Xa over thrombin (anti-Xa:anti-IIa ratio ~3.6:1).. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CALCIUM CHLORIDE 10% and ENOXAPARIN SODIUM depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CALCIUM CHLORIDE 10% is: IV: 500 mg to 1 g (5-10 m L of 10% solution) administered slowly at a rate not exceeding 0.5-1 m L/min; may be repeated every 1-3 days based on serum calcium levels.. The standard adult dose of ENOXAPARIN SODIUM is: 1 mg/kg subcutaneous every 12 hours or 1.5 mg/kg subcutaneous once daily. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CALCIUM CHLORIDE 10% and ENOXAPARIN SODIUM in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CALCIUM CHLORIDE 10% is classified as Category C. Animal reproduction studies have not been conducted with calcium chloride. It is not known whether calcium chloride can cause fetal harm when administered to a pregnant woman. Calc. ENOXAPARIN SODIUM is classified as Category A/B. Enoxaparin sodium does not cross the placenta and is not associated with teratogenicity in humans. However, there is a risk of hemorrhage during delivery. Use during pregnancy requ. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.